Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer

BACKGROUND: This multi-center RP2 study assessed activity/safety of ixabepilone + bevacizumab compared to ixabepilone in platinum-resistant/refractory ovarian/fallopian tube/primary peritoneal cancer. Additional objectives were to examine the role of prior bevacizumab and taxanes, and explore class...

Descripción completa

Detalles Bibliográficos
Autores principales: Roque, Dana M., Siegel, Eric R., Buza, Natalia, Bellone, Stefania, Silasi, Dan-Arin, Huang, Gloria S., Andikyan, Vaagn, Clark, Mitchell, Azodi, Masoud, Schwartz, Peter E., Rao, Gautam G., Reader, Jocelyn C., Hui, Pei, Tymon-Rosario, Joan R., Harold, Justin, Mauricio, Dennis, Zeybek, Burak, Menderes, Gulden, Altwerger, Gary, Ratner, Elena, Santin, Alessandro D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8853032/
https://www.ncbi.nlm.nih.gov/pubmed/35149854
http://dx.doi.org/10.1038/s41416-022-01717-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8853032/
https://www.ncbi.nlm.nih.gov/pubmed/35149854
http://dx.doi.org/10.1038/s41416-022-01717-6

Ejemplares similares